Patents by Inventor Kevin A. D'Amour
Kevin A. D'Amour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896622Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: November 8, 2019Date of Patent: February 13, 2024Assignee: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Publication number: 20220370184Abstract: A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.Type: ApplicationFiled: May 30, 2020Publication date: November 24, 2022Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Craig McGreevy, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
-
Publication number: 20220234006Abstract: A biocompatible membrane composite including a first layer (cell impermeable layer), a second layer (a mitigation layer), and a third layer (a vascularization layer) is provided. The mitigation layer may be positioned between the cell impermeable layer and the vascularization layer In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned on either side of the biocompatible membrane composite or within the biocompatible membrane composite to provide support to and prevent distortion of the membrane composite. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.Type: ApplicationFiled: May 30, 2020Publication date: July 28, 2022Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Evert Kroon, Laura Martinson, Craig McGreevy, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
-
Publication number: 20220233298Abstract: A biocompatible membrane composite that can provide an environment that is able to mitigate or tailor the foreign body response is provided. The membrane composite contains a mitigation layer and a vascularization layer. A reinforcing component may optionally be included to provide support to and prevent distortion of the biocompatible membrane composite in vivo. The mitigation layer may be bonded (e.g., point bonded or welded) or adhered (intimately or discretely) to an implantable device and/or cell system. The biocompatible membrane composite may be used as a surface layer for implantable devices or cell systems that require vascularization for function but need protection from the host's immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite may partially or fully cover the exterior of an implantable device or cell system. The mitigation layer is positioned between the implantable device or bioactive scaffold and the vascularization layer.Type: ApplicationFiled: May 30, 2020Publication date: July 28, 2022Inventors: Bahman Aghdasi, Timothy M. Bruhn, Kevin D'Amour, Edward Gunzel, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Christopher Folk, Craig McGreevy, Joseph Kakkassery
-
Publication number: 20220233299Abstract: Cell encapsulation devices for biological entities and/or cell populations that contain at least one biocompatible membrane composite are provided. The cell encapsulation devices mitigate or tailor the foreign body response from a host such that sufficient blood vessels are able to form at a cell impermeable surface. Additionally, the encapsulation devices have an oxygen diffusion distance that is sufficient for the survival of the encapsulated cells so that the cells are able to secrete a therapeutically useful substance. The biocompatible membrane composite is formed of a cell impermeable layer and a mitigation layer. The cell encapsulation device maintains an optimal oxygen diffusion distance through the design of the cell encapsulation device or through the use of lumen control mechanisms. Lumen control mechanisms include a reinforcing component that is also a nutrient impermeable layer, internal structural pillars, internal tensioning member(s), and/or an internal cell displacing core.Type: ApplicationFiled: May 30, 2020Publication date: July 28, 2022Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Edward Gunzel, Evert Kroon, Laura Martinson, Craig McGreevy, Scott Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
-
Publication number: 20220135948Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: ApplicationFiled: January 11, 2022Publication date: May 5, 2022Applicant: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Patent number: 11254916Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: GrantFiled: June 18, 2019Date of Patent: February 22, 2022Assignee: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Publication number: 20200316135Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: ApplicationFiled: November 8, 2019Publication date: October 8, 2020Applicant: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Patent number: 10517901Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: April 24, 2018Date of Patent: December 31, 2019Assignee: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Publication number: 20190359943Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: ApplicationFiled: June 18, 2019Publication date: November 28, 2019Applicant: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Patent number: 10370645Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: GrantFiled: June 3, 2016Date of Patent: August 6, 2019Assignees: Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hopsital, Inc., President and Fellows of Harvard CollegeInventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Publication number: 20180236006Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Applicant: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Patent number: 9980986Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: March 26, 2015Date of Patent: May 29, 2018Assignee: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Patent number: 9585917Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: August 8, 2011Date of Patent: March 7, 2017Assignee: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Publication number: 20160355787Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: ApplicationFiled: June 3, 2016Publication date: December 8, 2016Applicant: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Publication number: 20150265657Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: ApplicationFiled: March 26, 2015Publication date: September 24, 2015Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Publication number: 20140154801Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: ApplicationFiled: November 5, 2013Publication date: June 5, 2014Applicant: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Patent number: 8603811Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.Type: GrantFiled: October 17, 2011Date of Patent: December 10, 2013Assignee: ViaCyte, Inc.Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
-
Patent number: 8574905Abstract: Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.Type: GrantFiled: August 2, 2011Date of Patent: November 5, 2013Assignee: ViaCyte, Inc.Inventors: Kevin D'Amour, Emmanuel E. Baetge
-
Patent number: 8445273Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.Type: GrantFiled: August 29, 2011Date of Patent: May 21, 2013Assignee: ViaCyte, Inc.Inventors: Chad Green, Xiaojie Yu, Anne Bang, Eugene Brandon, Olivia Kelly, Alan D Agulnick, E Edward Baetge, Kevin A D'Amour, Thomas C Schulz, Allan J Robins